Correction Issued for Phase 3 Trials of Depemokimab in Chronic Rhinosinusitis

Correction on Depemokimab Trials Data

In a recent publication in The Lancet, authors including Gevaert and colleagues highlighted the findings from the ANCHOR-1 and ANCHOR-2 phase 3 trials, which assessed the efficacy and safety of depemokimab, an investigational treatment for chronic rhinosinusitis with nasal polyps. However, an important correction has been issued related to the data presented in the appendix of the article.

Details of the Trials

The ANCHOR-1 and ANCHOR-2 trials are pivotal studies that evaluated the safety profile and therapeutic effectiveness of depemokimab, administered biannually, in patients suffering from chronic rhinosinusitis with nasal polyps. The findings noted significant benefits for patients, which included improvements in nasal polyp size and overall sinus health.

Identified Error

On May 21, 2026, it was confirmed that there was an error in table S8 of the appendix, which contained erroneous data that could potentially mislead healthcare providers and researchers interpreting the results. This data has now been rectified and the authors provided updated information to ensure clarity and accuracy moving forward.

Implications for Future Research

This correction is critical as it reinforces the importance of data integrity in clinical research, particularly in studies involving chronic conditions like rhinosinusitis. The updated results are significant for clinicians looking to utilize depemokimab in their practice and for patients seeking effective treatment options.

Overall, the publication of corrected data contributes to the ongoing discourse around chronic rhinosinusitis management and underscores a commitment to transparency in medical research, enhancing trust in clinical findings. Further studies and data will likely provide additional insights into the long-term safety and efficacy of depemokimab.